Plain-English translation of NCT07432295 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called , given alongside two other cancer-fighting drugs ( and chemotherapy), to see if it helps people with advanced stomach, esophageal, or gastroesophageal junction cancer live longer and have better outcomes. About 180 people will be split into three groups: two groups will receive plus the standard treatment, and one group will receive the standard treatment alone. The medication is given through an IV (a needle in your vein) either every 2 or every 3 weeks, depending on which chemotherapy you receive.
Current treatments help some patients, but many people with this type of cancer do not respond well enough or relapse after treatment. Doctors believe adding this medication might help the body's immune system fight the cancer more effectively, especially in tumors with certain genetic markers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will visit the hospital or clinic regularly for IV infusions of the medication, along with your chemotherapy and infusions—either every 2 or every 3 weeks depending on your assigned group. You will have blood tests and imaging scans (like CT scans) at scheduled intervals to check how your cancer is responding. Treatment continues as long as the medication is working and you are not experiencing unacceptable side effects, typically over several months. Throughout the study, your medical team will carefully monitor you for any side effects and discuss your progress with you at each visit.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States
China
Japan